新辅助化疗联合保乳手术治疗乳腺癌的临床疗效分析  

Clinical Efficacy Analysis of Neoadjuvant Chemotherapy Combined with Breast-conserving Surgery in the Treatment of Breast Cancer

作　　者：王辉[1] 朱晓琳[2] 刘飞[1] 宋璐 WANG Hui;ZHU Xiaolin;LIU Fei;SONG Lu(Breast Disease Diagnosis and Treatment Center,Tai'an Central Hospital affiliated to Qingdao University,Tai'an,Shandong Province,271000 China;Medical Imaging Center,Tai'an Central Hospital Affiliated to Qingdao University,Tai'an,Shandong Province,271000 China)

机构地区：[1]青岛大学附属泰安市中心医院乳腺疾病诊治中心,山东泰安271000 [2]青岛大学附属泰安市中心医院医学影像中心,山东泰安271000

出　　处：《中外医疗》2023年第16期76-79,共4页China & Foreign Medical Treatment

基　　金：泰安市科技创新发展项目(政策引导类)(2021NS345)。

摘　　要：目的探讨乳腺癌患者应用新辅助化疗联合保乳手术治疗的临床疗效。方法方便选择2018年1月—2021年1月青岛大学附属泰安市中心医院收治的82例乳腺癌患者为研究对象,随机将患者分为观察组(新辅助化疗方案联合保乳手术,41例)与对照组(改良根治术,41例)。比较两组患者的临床治疗效果、治疗前后的免疫功能、生活质量评分,统计两组不良反应发生情况。结果两组患者的转移率、复发率对比,差异无统计学意义(P>0.05)。治疗后,观察组各项生活质量评分分别为(89.48±3.23)分、(86.91±3.72)分、(87.25±4.17)分均高于对照组,免疫功能CD3^(+)(58.04±5.42)%、CD4^(+)(40.01±5.80)%、CD4^(+)/CD8+(1.85±0.34)水平高于对照组,差异有统计学意义(t=8.181、7.912、6.234、3.126、5.892、5.321,P<0.05);观察组不良反应发生率低于对照组(4.88%vs 19.51%),差异有统计学意义(χ^(2)=4.100,P<0.05)。结论新辅助化疗联合保乳手术能提升乳腺癌患者的免疫功能,手术安全性较高,对改善患者预后生活质量有积极意义。Objective To investigate the clinical efficacy of neoadjuvant chemotherapy combined with breastconserving surgery for breast cancer patients.Methods A total of 82 patients with breast cancer admitted to Tai'an Central Hospital Affiliated to Qingdao University from January 2018 to January 2021 were conveniently selected,randomly divided into observation group(neoadjuvant chemotherapy combined with breast-conserving surgery,41 cases)and control group(modified radical mastectomy,41 cases).The clinical treatment effect,immune function and quality of life scores before and after treatment were compared between the two groups,and the incidence of adverse reactions in the two groups was counted.Results There was no statistically significant difference in the metastasis rate and recurrence rate between the two groups(P>0.05).After treatment,the various quality of life scores of the observation group were(89.48±3.23)points,(86.91±3.72)points,and(87.25±4.17)points,respectively,which were higher than those of the control group,and the immune function CD3^(+)(58.04±5.42)%,CD4^(+)(40.01±5.80)%,CD4^(+)/CD8^(+)(1.85±0.34)levels were higher than those of the control group,the difference was statistically significant(t=8.181,7.912,6.234,3.126,5.892,5.321,P<0.05);the incidence of adverse reactions in the observation group was lower than that in the control group(4.88%vs 19.51%),and the difference was statistically significant(χ^(2)=4.100,P<0.05).Conclusion Neoadjuvant chemotherapy combined with breast-conserving surgery can enhance the immune function of breast cancer patients with high surgical safety.It has positive significance for improving patients'prognosis and quality of life.

关 键 词：乳腺癌 新辅助化疗 保乳手术 疗效 免疫功能 生活质量 不良反应 

分 类 号：R737.9[医药卫生—肿瘤]